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Abstract
Purpose of Review In this review, we summarise the evidence
on the association between cardiovascular disease (CVD) and
cognitive impairment and explore the role of the nitric oxide
(NO) pathway as a causal mechanism.
Recent Findings Evidence from epidemiological studies sug-
gests that the presence of CVD and its risk factors in midlife is
associated with an increased risk of later life cognitive impair-
ment and dementia. It is unclear what is driving this associa-
tion but risk may be conveyed via an increase in neurodegen-
eration (e.g. amyloid deposition), vascular changes (e.g. small
vessel disease) and mechanistically due to increased levels of
oxidative stress and inflammation as well as changes in NO
bioavailability.
Summary CVDs and dementia are major challenges to global
health worldwide. The NO pathway may be a promising bio-
logical candidate for future studies focused on reducing not
only CVD but also risk of cognitive decline and dementia.
Keywords Cardiovascular disease . Cognitive impairment .
Dementia . Endothelial function . Nitric oxide
Introduction
Midlife cardiovascular disease (CVD) and vascular risk fac-
tors have been consistently associated with an increased risk
of later life cognitive impairment and dementia [1–3]. The
underlying mechanisms explaining how CVDs and their risk
factors negatively affect cognitive function are complex, re-
main unclear and will likely vary depending on the type, age
of onset, duration and severity of disease and co-occurring risk
factors such as low educational attainment and disease-related
co-morbidity [4]. In addition to neurovascular (e.g. small ves-
sel disease) and neuropathological (e.g. amyloid disposition)
processes, other biological pathways are thought to be in-
volved, such as the nitric oxide (NO), inflammatory (e.g. in-
terleukin-6) and oxidative stress pathways. Each of these pro-
cesses and the NO pathway have been implicated in the path-
ophysiology of CVD, vascular risk factors, cerebrovascular
disease (e.g. stroke), cognitive impairment and dementia.
However, the direction of causality is yet to be established.
The aim of this review is to firstly provide an overview of
studies investigating the link between CVD and cognitive
function including risk of dementia focusing on midlife to
later life; and, secondly, discuss how the NO pathway can
explain the risk for dementia conferred by CVD and its risk
factors. Determining the mediating effect of the NO pathway
between CVD and cognitive impairment and dementia is
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important to (1) identify and validate sensitive biomarkers to
discriminate individuals at greatest risk of future cognitive
decline and dementia; (2) test the efficacy of targeted nutri-
tional interventions enhancing NO availability and whether
these exert downstream positive effects on brain metabolic
and vascular regulation; and, (3) inform dietary and lifestyle
prevention programmes to concomitantly reduce incidence of
CVD and dementia in older aged populations.
CVD, Cognitive Function and Dementia
Systematic reviews consistently report impairment in cogni-
tive function and an increased risk of dementia (including all-
cause, Alzheimer’s disease and vascular dementia) in individ-
uals with a history of CVD including coronary heart disease,
heart failure and atrial fibrillation [5–8]. In addition, vascular
risk factors such as hypertension, hyperlipidaemia, diabetes,
excess adiposity, metabolic syndrome and physical inactivity,
as well as CVD risk prediction models (e.g. the Framingham
CVD and coronary heart disease risk scores), have been asso-
ciated with cognitive decline and future risk of cognitive im-
pairment and dementia in older aged populations [9••, 10–12].
Although general cognitive impairments have been shown in
relation to CVD and vascular risk factors, deficits appear ini-
tially and more predominantly within attention, executive
function (i.e. higher level cognitive skills associated with
mental control and self-regulation such as planning, decision
making and inhibition) and processing speed domains
[13–15]. Where associations have not been reported, studies
have been found to be under-powered for cognitive/dementia
outcomes, have used limited neuropsychological tests restrict-
ed to a single or few cognitive domains and generally have
had short follow-up times [9••]. The results may also depend
on the characteristics of the study population (e.g. age, sex,
ethnicity, disease severity), follow-up length, whether disease
is controlled (pharmacological vs. non-pharmacological),
presence of disease-related co-morbidity and population sam-
pling (i.e. clinical vs. population based).
Indeed, the role of CVD and its risk factors in the develop-
ment of cognitive impairment and dementia becomes less
prominent, and potentially protective, with advancing age.
Obesity (measured using the body mass index or waist-to-
hip ratio) [16–18], hypertension [2], the metabolic syndrome
[19] and hypercholesterolaemia [20–22] have been associated
with non-significant or even protective effects on risk of cog-
nitive decline and dementia in the very old population, defined
as persons aged ≥85 years. Each of these conditions may have
a distinct biological substrate explaining the reduced risk of
cognitive impairment and dementia in this age group. For
example, the obesity paradox could be explained by the role
of adipose tissue in body weight regulation and as an energy
provider for costly physiological processes (e.g. immune
function, glomerular filtration or haematopoiesis) [23].
These functions may become vital at later stages of life when
the capacity of frail bodies to cope with stressors and adver-
sities is diminished and all available resources are required to
help maintain physical and mental health [24]. The specific
mechanisms that could explain the hypertension findings are
still uncertain, but a higher blood pressure may maintain brain
tissue vascular perfusion and a potential drop in blood pres-
sure could be expected in individuals developing dementia
due to dysregulation of autonomic regulatory mechanisms
controlling vascular tone [25, 26]. Regarding the metabolic
syndrome, the lack of an association in very old age groups
could be due to how the metabolic syndrome is measured (i.e.
cut-offs may not be age sensitive) and the fact that it is not a
single entity but rather an amalgamation of several cardio-
metabolic risk factors [27]. Regarding cholesterol, higher
levels may be protective at very old age since cholesterol is
an essential component in the structure of the myelin sheath of
neurons, key for efficient transmission of nerve impulses and
brain functioning [28, 29].
These results highlight that CVD and its risk factors are
associated with cognitive impairment and dementia in
middle-aged and young-old (i.e. 65–84 years of age) individ-
uals. Therefore, it seems that the timing of disease (e.g. mid
versus later life) and sample characteristics (e.g. age) are im-
portant in determining the strength as well as the direction (i.e.
risk versus protective) of any association. Additional studies
are needed to understand whether the tracking of CVD and its
risk factors across the life course (i.e. duration of disease) and
timing when the condition occurs influence the pattern of
associations between CVD and its risk factors with cognitive
function and dementia.
Structural and Functional Brain Changes Associated
with CVD and Vascular Risk Factors: Links
to Cognitive Impairment and Dementia
CVD can alter the brain structure and functioning including an
increase in white matter lesions, small vessel disease, micro-
bleeds, cerebral infarcts, grey matter atrophy and regional
structural alterations (e.g. in the hippocampus), in addition to
cerebral hypoperfusion and increased amyloid disposition [30,
31]. Each is a potential pathological mediator in the CVD-
cognition pathway involved in the initiation and progression
of cognitive symptoms [3]. Further, a recent review of brain
changes associated with vascular risk factors including hyper-
tension, obesity, hyperlipidaemia, diabetes and the metabolic
syndrome also found evidence of brain structural and func-
tional changes even in asymptomatic individuals that have
been linked to cognitive function [32]. Findings from autopsy
studies suggest additive or synergistic links between
Alzheimer’s disease and vascular (i.e. cerebral amyloid
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angiopathy and small vessel disease) pathologies on the influ-
ence and promotion of cognitive impairment and risk of de-
mentia in older aged populations [33]. Taken together, it
emerges that an integrated, complex network of vascular, met-
abolic and neural mechanisms regulating cerebral blood flow
and cognitive processes are likely to be important components
in the pathophysiology underlying cognitive impairment and
dementia in the presence of vascular disease.
Inflammation and Oxidative Stress
In all age groups, including the very old, a significant
and increased risk of cognitive decline and dementia has
been associated with high inflammation (e.g. C-reactive
protein and interleukin-6) and oxidative stress (e.g. ho-
mocysteine) levels [10, 34]. Both oxidative stress and
inflammation are closely connected to the pathophysiol-
ogy of CVD and neurological diseases such as dementia
[35, 36]. Regarding cardiovascular health, higher levels
of oxidative stress and inflammation have been linked
to the pathogenesis of atherosclerosis [37]. In relation to
the brain, higher levels of oxidative stress and inflam-
mation have been linked to impaired cellular function
which may have direct effects on neuronal structure
and integrity [38]. Further, inflammation is thought to
be important in neurodegeneration, as a consequence as
well as contributor to the development of some of the
classic hallmarks of Alzheimer’s disease pathology such
as amyloid-beta plaques [39]. Oxidative stress and in-
flammation therefore contribute to the pathogenesis of
CVDs and dementia and a key intermediate mechanistic
link between these two conditions and its risk factors
maybe be represented by the NO pathway given the
pleiotropic roles of NO in the regulation of vascular,
metabolic, immune and cognitive functions [40].
Physiological Roles of Nitric Oxide Production
in Brain Function
NO is a reactive gas secreted in endothelial cells by the endo-
thelial isoform of the enzyme NO synthase and is tonically
released to control systemic vascular tone (i.e. arterial tone,
cardiac output and venous capacitance) and platelet aggrega-
tion [41]. The vascular endothelium represents a physical and
functional interface between circulating blood corpuscolate,
fluid blood components (e.g. nutrients) and tissue metabolic
processes [42]. Damage to the vascular endothelium is con-
sidered as a key pathogenetic element in the onset of athero-
sclerosis and CVD [43].
NO synthase converts L-arginine into an equimolar amount
of NO and citrulline (enzymatic synthetic pathway) [41]. NO
can also be generated by an alternative non-enzymatic path-
way. This involves a two-step reduction of inorganic nitrate
into nitrite by oral bacteria (first step) and further reduction of
nitrite into NO in the stomach or vascular periphery by the low
gastric pH and reductase activity of selected enzymes (second
reducing step) [44]. A description of the NO synthetic path-
ways and pleiotropic effects on physiological functions is pro-
vided in Fig. 1.
The production of NO in the brain and its role in the control
of neuronal functions has been comprehensively investigated in
animal studies [46]. However, little evidence on the role of NO
in brain function in humans exists. In a small number of studies,
it has been demonstrated that NO is involved in learning and
memory processes [47]. For example, NO donors
(molsidomine, S-nitroso-N-acetylpenicillamine and sodium ni-
tro-prussiate) and L-arginine have been found to help increase
NO availability in the brain resulting in improvements in learn-
ing and memory [48, 49]. In addition, methyl analogues of L-
arginine (i.e. asymmetric dimethylarginine, ADMA or nitro-L-
arginine methyl ester), which are known to inhibit NO synthe-
sis, have been associated with cognitive impairment in older
adults with and without dementia [50, 51].
Fig. 1 Pathways involved in the
synthesis of nitric oxide and
downstream physiological
effects. NO3 nitrate, NO2 nitrite,
NOS nitric oxide synthase.
(Modified from Jones AM. Sports
Medicine (Auckland, New
Zealand). 2014; 44 (Suppl 1):35–
45) [45]
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The beneficial effects of NO on brain function (e.g. learn-
ing and memory) appear to be mediated by several mecha-
nisms. These include nitrosylation of N-methyl-D-aspartic ac-
id (NMDA) and augmentation of excitability via modulation
of voltage-gated potassium channels, which can mediate a
calcium-dependent activation of neuronal NO synthase and
downstream canonical cyclic guanosine monophosphate
(cGMP)-mediated signalling. NO also regulates other path-
ways via the post-translational modification (S-nitrosylation
and 3-nitrotyrosination) of proteins involved in synaptic trans-
mission and intracellular trafficking [52]. However, evidence
also suggests that high NO generation could lead to abnormal
protein modifications and impact on the pathogenesis of var-
ious neurodegenerative diseases, including Parkinson’s dis-
ease and Alzheimer’s disease [53••]. Hence, a better under-
standing of the physiological role of NO on brain function and
identification of the specific regulatory mechanisms may rep-
resent an important diagnostic and therapeutic strategy for the
maintenance of cognitive function.
Endothelial Dysfunction, NO and Cognitive
Impairment
Endothelial function is closely linked to the control of cere-
brovascular reactivity, which is essential for creating a
favourable environment for neurons, by maintaining energy-
dependent processes and removing metabolic waste [54–56].
It has been suggested that impaired cerebrovascular reactivity
is not only related to CVDs, but can also be associated with
dementia [57]. Studies have explored the association between
physiological (i.e. flow-mediated dilation and pulse wave ve-
locity) and circulating biomarkers of endothelial function and
NO bioavailability (i.e. nitrate, nitrite, ADMA) with cognitive
impairment [51, 58–61]. Flow-mediated dilation was found to
be lower in patients with Alzheimer’s disease compared to that
of controls and was significantly correlated directly with glob-
al cognitive function (Mini Mental State Examination scores)
and Clinical Dementia Rating scores (inverse association)
[62]. Similarly, pulse wave velocity has been found to be sig-
nificantly higher in Alzheimer’s disease patients compared to
controls without cognitive impairment [63]. Patients with
Alzheimer’s disease have also been found to have higher plas-
ma concentrations of ADMA and lower levels of nitrate com-
pared to healthy controls [51, 64]. In contrast, two studies have
reported lower ADMA concentrations in cerebrospinal fluid of
Alzheimer’s disease patients compared to healthy controls [65,
66] whereas one study found no significant differences be-
tween Alzheimer’s disease patients and age-matched control
subjects [67]. Inconsistencies in findings could be related to
differences in the stages of dementia across studies [67] and
the degree of methylation of arginine residues in the brain due
to a reduction of S-adenosyl-L-methionine [68]. S-Adenosyl-
L-methionine concentrations are decreased in cerebrospinal
fluid of Alzheimer’s disease patients which could have an
effect on the generation and release of ADMA in the brain
[69]. The net effect of this decrease in ADMA concentrations
is an increased generation of NO in the brain which could be
more susceptible to react with oxidative species and generate
peroxynitrite, thus contributing to the pathogenesis of
Alzheimer’s disease [70, 71]. Together, these results highlight
the role of endothelial dysfunction in the pathophysiology of
dementia and suggest that physiological markers of endothe-
lial dysfunction are more closely associated with cognition
compared to circulating biomarkers of NO.
It has also been suggested that impaired NO and endothe-
lial dysfunction could be associated with cognitive impair-
ment, and the development of Alzheimer’s disease, possibly
due to dysfunction of cerebral blood flow and reduced oxygen
supply to the brain [72]. Disruption of the neurovascular func-
tion could therefore be considered as a major risk factor for
cerebral vascular deregulation, which could be affected by
compromised NO activity. Manukhina et al. found that a re-
duced NO production in rats, following the administration of
the NO synthase inhibitor NG-nitro-L-arginine methyl ester
(L-NAME), increased the harmful effects of beta-amyloid
and was linked to memory deficits like those observed in
Alzheimer’s disease, whereas the administration of NO do-
nors showed a protective effect on beta-amyloid deposition
[73]. As beta-amyloid is the primary component of the extra-
cellular plaques and is increased in neurodegenerative disease,
investigating the association between NO and beta-amyloid
might give a better understanding of how vascular function
is linked to neuronal damage.
NO-Targeted Nutritional Interventions
The biosynthesis of NO is highly dependent on arginine and
inorganic nitrate intake since they are the main substrates for
the enzymatic and non-enzymatic pathways, respectively. In
addition, NO synthesis can be enhanced by the presence or
activity of other nutrients such as vitamin C, polyphenols or
polyunsaturated fatty acids [41, 44]. Arginine supplementa-
tion has been shown to improve cognitive function and cere-
bral blood flow in 16 older aged adults (mean age 79 years)
[74]. However, more robust and larger clinical trials are need-
ed to confirm these preliminary results. Dietary nitrate supple-
mentation has also been associatedwith significant benefits on
blood pressure and endothelial function [75•, 76]. A few stud-
ies have investigated the effect of dietary nitrate on cerebral
blood flow, and a summary of these studies is described in
Table 1. Overall, dietary nitrate has been found to enhance
cerebral blood flow in humans of different ages and has been
associated with improved cognitive processes [77–79].
However, studies are characterised by a short duration, small
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sample size and have restricted recruitment to healthy individ-
uals with normal cognitive function. Therefore, it remains to
be established whether nitrate supplementation over longer
time periods influences cognitive function in older individuals
(≥60 years) with cognitive impairment.
Implications for Research
The findings highlight that CVDs and vascular risk factors are
major risks for the onset of cognitive decline and dementia.
However, timing of the disease matters as the association
varies with age. Further, while there is some preliminary evi-
dence on the association between biomarkers of NO availabil-
ity and cognitive processes in humans, most of research is still
limited to animal models. However, these studies have dem-
onstrated a role of NO-related mechanisms in the regulation of
cognitive processes alongside the established effects on blood
flow and cellular metabolism. These data can therefore prompt
the development of research hypotheses in this area, such as to
explore the association in longitudinal studies between phys-
iological (i.e. flow-mediated dilation and pulse wave velocity)
and biochemical (nitrate, nitrite, ADMA) biomarkers with
prospective changes in cognitive function and risk of incident
dementia. Positive results may have important diagnostic im-
plications for the development of risk prediction and screening
models for the early identification of individuals at risk of and
with cognitive decline and dementia. Further, two nutrients
(i.e. arginine and inorganic nitrate) are the precursors of NO
in the enzymatic and non-enzymatic synthetic pathways and
therefore dietary patterns (e.g. Mediterranean diet, DASH di-
et) or foods rich in these nutrients (e.g. lettuce, rocket, cab-
bage, eggs, beetroot, nuts) may be examples of targeted nutri-
tional interventions aimed at increasing NO bioavailability
and potentially reducing risk of CVD as well as improving
cognitive function. However, the effects derived from the sup-
plementation of these nutrients on cognitive function have not
been explored in human clinical trials.
Conclusions
With a rapidly ageing population, CVDs and dementia are
major challenges to global health and future health care pro-
vision. A critical characteristic of these trends is that the larg-
est proportion of cases will be in low- and middle-income
countries where public health resources and clinical services
are limited. Therefore, sensitive and affordable biomarkers for
the early identification of CVD and dementia risk are an ur-
gent priority alongside testing effective nutritional and life-
style preventative and treatment strategies to maintain cogni-
tive function. The NO pathway may be a promising biological
candidate to respond directly to these requisites (biomarkersTa
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and interventions) and future studies testing the role of NO as
a mediator of the association between cardiovascular diseases
and cognitive function are awaited.
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